The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most ...

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...

City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based ...

Macular degeneration usually refers to the age-related degenerative changes in the retina that can result in loss of central vision. It is caused by abnormal blood vessel growth (a condition ...

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ... and ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

In the last 20 years, there have been rapid advances in the treatment options ... patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...